Skip to content
lifestyle.smsolar.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Arcutis Biotherapeutics, Inc.
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
October 6, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
September 29, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 2, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
July 8, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
June 30, 2026
1
2
3
Next Page
→